Mycoplasma Galliscepticum positive serum (DAGF-117)

Mycoplasma Galliscepticum positive serum

Alternative Names
Mycoplasma gallisepticum; MG
Batch dependent - please inquire should you have specific requirements.
Store at -20°C or lower. Avoid repeated freeze/thaw cycles
Antigen Description
In blood, the serum is the component that is neither a blood cell (serum does not contain white or red blood cells) nor a clotting factor; it is the blood plasma not including the fibrinogens. Serum includes all proteins not used in blood clotting (coagulation) and all the electrolytes, antibodies, antigens, hormones, and any exogenous substances (e.g., drugs and microorganisms). A study of serum is serology, and may also include proteomics. Serum is used in numerous diagnostic tests, as well as blood typing.
Mycoplasma gallisepticum; MG


Have you cited DAGF-117 in a publication? Let us know and earn a reward for your research.

Related Products

Dog Serum (DAG124)
Pig Serum (DAG126)
Rabbit Serum (DAG138)

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Active management of severe hyponatraemia is associated with improved mortality


Authors: Garrahy, Aoife; Cuesta, Martin; Murphy, Brian; O'Reilly, Michael W.; Tormey, William P.; Sherlock, Mark; Thompson, Chris J.

Objective: Severe hyponatraemia (plasma sodium concentration, pNa <120 mmol/L) is reported to be associated with mortality rates as high as 50%. Although there are several international guidelines for the management of severe hyponatraemia, there are few data on the impact of treatment. Design and methods: We have longitudinally reviewed rates of specialist input, active management of hyponatraemia, treatment outcomes and mortality rates in patients with severe hyponatraemia (pNa <120 mmol/L) in 2005, 2010 and 2015, and compared the recent mortality rate with that of patients with pNa 120-125 mmol/L. Results: Between 2005 and 2010 there was a doubling in the rate of specialist referral (32 to 68%, P = 0.003) and an increase in the use of active management of hyponatraemia in patients with pNa <120 mmol/L (63 to 88%, P = 0.02), associated with a reduction in mortality from 51 to 15% (P < 0.001). The improved rates of intervention were maintained between 2010 and 2015, but there was no further reduction in mortality. When data from all three reviews were pooled, specialist consultation in patients with pNa <120 mmol/L was associated with a 91% reduction in mortality risk, RR 0.09 (95% CI: 0.03-0.26), P < 0.001. Log-rank testing on in-hospital survival in 2015 found no significant difference between patients with pNa <120 mmol/L and pNa 120-125 mmol/L (P = 0.56). Conclusion: Dedicated specialist input and active management of severe hyponatraemia are associated with a reduction in mortality, to rates comparable with moderate hyponatraemia.

Characterisation and bioactivities of an exopolysaccharide from an Antarctic bacterium Shewanella frigidimarina W32-2


Authors: Chen, Yimin; Gao, Peili; Tang, Xu; Xu, Changan

The continent of Antarctica breeds numerous special extremophiles that have adapted to the extreme variation of environment with a wide range of novel biodiversity. A cold-adapted bacterium Shewanella frigidimarina W32-2, isolated from Antarctic sediments, was identified to be a promising candidate of exopolysaccharides (EPS) production. In the present study, the physiochemistry and bioactivities of the EPS were investigated to promote its application in aquaculture. Physiological characterisation of this strain was firstly performed by means of combined API 20NE and API ZYM tests. A biochemical analysis revealed that the EPS contained a majority of carbohydrates (56.34 +/- 1.29%), uronic acids (8.23 +/- 0.55%) and high content of sulphate groups (35.43 +/- 1.84%), which were also confirmed by the FTIR spectrum showing various functional groups with potential antioxidant activities. The bioactive properties of the EPS in vitro and in vivo were both evaluated. The effect of the EPS on the non-specific immunity of red tilapia via serum injection exhibited 100% of survival rate. Improvement of activities in different serum enzymes, including AKP, ACP, SOD, CAT and LZM, was observed generally at the early stage of EPS treatment (except LZM at later stage). This study explores novel EPS from an extremophile exhibiting powerful bioactivity with immense potential in aquaculture sustainability.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket